Home | Welcome to Contract Pharma   
Last Updated Thursday, November 27 2014
Print RSS Feed

Financial Report: GSK



Published April 30, 2014
GSK
 
1Q Revenues: £5.6 billion (-10%)
 
1Q Earnings: £1.5 billion (-18%)
 
Comments: Pharmaceutical sales were £3.8 billion, down 4% and Vaccines sales were £658 million, up 3% with growth in Europe (+3%), Emerging Markets (+2%), Japan (+13%), offset by a 10% decline in the U.S., impacted by continued Advair declines (-20%) and quarterly volatility in wholesaler/retailer stocking patterns. HIV sales were up 4%, driven by uptake of recently launched integrase inhibitor, Tivicay. Oncology product sales were up 31% to £108 million, driven by Votrient and Promacta, and the recent launches of Tafinlar and Mekinist. Consumer Healthcare revenue was flat at £1.1 million. In the quarter, the company announced a $20 billion three-part deal with Novartis involving its Consumer Healthcare, Vaccines and Oncology businesses.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On